Liver transplant recipient, hepatitis B
Conditions
Interventions
A:Immune state, HBIG, nucleotide (s) protocol 1
B:Immune state, small dose of HBV vaccine, HBIG, nucleotide (s) protocol 2
C:Immune state, small dose of HBV vaccine, nucleotide(s) protocol 3
D:Immune state, large dose of HBV vaccine, HBIG, nucleotide (s) protocol 4
E:Immune state, large dose of HBV vaccine, nucleotide(s) protocol 5
Sponsors
Tianjin First Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Informed consent signed by the patient or his legal guardian; 2. male or female patients aged 18~70 years; 3. preoperative HBV-DNA replication is negative, HBsAg positive, HBsAb negative, and postoperative hepatitis B surface antibody of patient are positive 3 years after liver transplantation; 4. the main detection indexes of the patients were: 1) liver function: normal; 2) renal function: normal.
Exclusion criteria
Exclusion criteria: 1. Women who are in pregnancy (urine / blood pregnancy test positive) or lactating; 2. Men or women with pregnancy plans in the last year; 3. Patients who had uncontrollable infection during 4 weeks before the entry of the group; 4. HIV infected patients; 5. Patients are allergic, allergic to macromolecules, such as antibodies or cytokines; 6. Patients participated in other clinical trials before entering the group; 7. Patients with systemic use of hormones before entering the group (except for inhaled corticosteroids); 8. patients suffering from mental illness; 9. patients have drug abuse / addiction; 10. There are other inappropriate situations for patients judged by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| anti-HBs titier;HBVcccDNA; | — |
Countries
China
Contacts
Public ContactShen Zhongyang
Tianjin First Central Hospital
Outcome results
None listed